PhoenixBio

Basic Information

Stock Code
6190
Industry
Services
Category Detail
Biotechnology & Pharmaceuticals
Prefecture
Hiroshima Prefecture
Establishment Year
March 2002
Listing Year
March 2016
Official Website
https://phoenixbio.co.jp/
TSE Information
TSE Information
Yahoo! Finance
Yahoo! Finance
Other Companies
Kojin Bio, Linical, Transgenic Group, Shin Nihon Science, DNA Chip Research Institute, Axel M, IGS, H.U. Group Holdings, Falco Holdings, BML, Human Metabolome Technologies, Fureasu

Overview

PhoenixBio is a bio-venture originating from Hiroshima, established in 2002. It specializes in commissioned pharmacological efficacy testing and is an industry leader with strengths in chimeric mouse production.

Current Situation

PhoenixBio maintains stable revenue in fiscal 2023 from pharmacological efficacy testing and chimeric mouse production commissioned services. As a bio-venture from Hiroshima University, its production technology for human immunodeficient mice (chimeric mice) serves as the source of its competitive advantage. It continues to grow amid increasing demand from pharmaceutical companies and research institutions, strengthening its presence in domestic and international clinical trial commissioned markets. To differentiate from competitors, it focuses on advanced mouse model development and enhancement of pharmacological evaluation technologies. New investments are aimed at expanding R&D facilities and improving production capacity, reinforcing the foundation for sustainable growth. In recent years, it has advanced improvements in production processes incorporating environmental considerations and strengthened regulatory compliance. It plans new customer development and overseas expansion as growth drivers after 2025, aiming to secure mid- to long-term competitiveness and sustainable business operations.

Trivia

Interesting Facts

  • Venture from Hiroshima University holding top-class domestic chimeric mouse production technology
  • Industry-leading market share in chimeric mice for pharmacological testing
  • High evaluation from domestic and international sources for improved model accuracy in animal testing
  • Strength in technological accumulation from over 20 years of R&D since establishment
  • Unique animal model provider in the CRO industry
  • Technology base enabling differentiation from competitors in clinical trial support
  • Largest scale production of human immune system-reconstructed mice in Japan
  • Advanced company progressing with environmentally considerate breeding technology
  • Unique business model in Japan's bio-venture scene
  • Growth driven by increasing demand accompanying advanced pharmaceutical development

Hidden Connections

  • Accelerated technology development through long-term collaboration with Hiroshima University School of Medicine
  • Exclusive contractual relationships with multiple major pharmaceutical companies
  • Participation in large-scale joint research projects with domestic medical and research institutions
  • Experience in joint development of new breeding systems considerate of animal welfare
  • Personnel exchanges of research resources with some competing companies
  • Promoting global expansion through partnerships with overseas CROs
  • Strengthened analysis technology through collaboration with specific bioinformatics companies
  • Numerous technology presentations at related industry exhibitions

Future Outlook

Growth Drivers

  • Increasing demand for advanced pharmacological testing in the pharmaceutical industry
  • Global demand expansion due to internationalization of pharmaceutical development
  • Competitiveness in advanced chimeric mouse model development
  • Efficiency gains from AI and data analysis technology introduction
  • Rapid growth of the biotechnology industry
  • Demand for new technologies emphasizing animal welfare
  • Service enhancements adapting to changing domestic and international regulatory environments
  • Increased model demand from expansion in basic research fields
  • Expansion of environmental sustainability orientation
  • Deepening of university-corporate collaborations
  • Expanded trust acquisition through regulatory compliance
  • Differentiation through advanced disease model development

Strategic Goals

  • Expand market share in pharmacological testing commissions domestically and internationally
  • Establish leading position in new chimeric mouse model development
  • Double production capacity through R&D facility expansion
  • Operate breeding systems aiming for zero environmental impact
  • Promote automation of pharmacological evaluation through AI analysis technology
  • Strengthen collaborations with overseas CROs for global expansion
  • Introduce cutting-edge technology compliant with animal welfare regulations
  • Achieve annual sales of 10 billion yen
  • Expand and diversify multi-disease models
  • Establish sustainable research foundation

Business Segments

Pharmacological Efficacy Testing Commissioned Services

Overview
Commissioned services for pharmacological efficacy testing using animal models for pharmaceutical development.
Competitiveness
Advanced chimeric mouse technology originating from Hiroshima University
Customers
  • Pharmaceutical Companies
  • Bio-ventures
  • University Research Institutions
  • Public Research Institutes
Products
  • Chimeric Mouse Production
  • Pharmacological Evaluation Testing
  • GLP Testing Support

Model Animal Manufacturing & Sales

Overview
Specializing in manufacturing and sales of research model mice.
Competitiveness
High-quality model production through proprietary immunodeficient technology
Customers
  • Pharmaceutical Companies
  • Research Institutions
  • Commissioned Testing Companies
Products
  • Humanized Immunodeficient Mice
  • Genetically Modified Models
  • Cancer Model Mice

Research Reagents & Equipment Sales

Overview
Sales of experimental reagents and related equipment.
Competitiveness
Thoroughly quality-controlled product lineup
Customers
  • University Labs
  • Corporate Research Institutes
  • Commissioned Testing Institutions
Products
  • Research Antibodies
  • Cell Culture Media
  • Experimental Equipment

Data Analysis Commission

Overview
Commissioned services for analysis of testing data and report creation.
Competitiveness
Specialized expertise and high-precision analysis technology
Customers
  • Pharmaceutical Companies
  • CROs
  • Research Institutions
Products
  • Pharmacological Testing Analysis
  • Statistical Analysis
  • Report Creation

Competitive Advantage

Strengths

  • High expertise in chimeric mouse production technology
  • Proprietary technology base from Hiroshima University
  • Stable customer base in pharmacological testing commission field
  • Active investment in R&D
  • Robust system for providing high-quality animal models
  • GLP-compliant testing capabilities
  • Abundant track record in drug evaluation
  • High reliability within the industry
  • Collaborations with domestic and international research institutions
  • Advanced data analysis technology

Competitive Advantages

  • Technological leadership in chimeric mouse production
  • Technological superiority based on long-term collaboration with Hiroshima University
  • High trust gained from pharmaceutical companies
  • Provision of humanized immunodeficient mice not available from competitors
  • Comprehensive pharmacological testing commissioned services
  • High-quality product management and regulatory compliance
  • Flexibility in new mouse model development
  • Comprehensive testing data analysis and support systems
  • Lower cost and higher precision compared to competitors
  • Presence as a partner in pharmaceutical development

Threats

  • Intensifying competition due to technological innovations by other companies
  • Risks from stricter pharmaceutical development regulations
  • Rising social criticism against animal testing
  • Decrease in commissioned projects due to research funding cuts
  • Expanding competition with overseas companies
  • Market fluctuations from emergence of new technologies
  • Potential intellectual property disputes
  • Burden of changes in testing systems due to legal amendments

Innovations

2023: Development of New Immunodeficient Mouse Model

Overview
Introduced a new model that more accurately recapitulates the human immune system, improving pharmacological evaluation accuracy.
Impact
Achieved 20% increase in testing commissions

2022: Introduction of Automated Testing Data Analysis Technology

Overview
Utilized AI technology to improve efficiency and accuracy of pharmacological testing data analysis.
Impact
Reduced analysis time by 30%

2021: Major Upgrade of Production Equipment

Overview
Updated automation equipment in mouse production lines, significantly improving production efficiency.
Impact
25% increase in production capacity

2024: Introduction of Environmentally Friendly Breeding System

Overview
Adopted energy-saving and resource-efficient laboratory animal breeding equipment to promote sustainability.
Impact
15% reduction in CO2 emissions

2023: Expansion of Chimeric Mouse Applications

Overview
Expanded the range of applications through new disease model development, broadening new drug candidate evaluation.
Impact
30% expansion in customer needs coverage

Sustainability

  • Introduction of low-environmental-impact breeding equipment
  • Efforts to improve laboratory animal welfare
  • Enhanced waste recycling
  • Thorough energy-saving and water-saving measures
  • Participation in local environmental conservation activities